Current problems and needs in the treatment of pT1 G3 bladder carcinoma

International Urology and Nephrology

Volumn 33, Issue 1, 2001, Pages 29-40

  Martínez Portillo, Francisco Jose ^a   Alken, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bladder cancer; Treatment options

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CYTOSTATIC AGENT; EPIRUBICIN; IMMUNOMODULATING AGENT; MITOMYCIN C;

ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CYSTECTOMY; DRUG INSTILLATION; DRUG MECHANISM; HUMAN; PROGNOSIS; REVIEW; TOXICITY; TRANSURETHRAL RESECTION; URINARY DIVERSION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLADDER TUMOR; DISEASE FREE SURVIVAL; FEMALE; INTRAVESICAL DRUG ADMINISTRATION; MALE; METHODOLOGY; MORTALITY; NEEDLE BIOPSY; NEEDS ASSESSMENT; PATHOLOGY; RISK ASSESSMENT; SURVIVAL; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVESICAL; BCG VACCINE; BIOPSY, NEEDLE; BLADDER NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; HUMAN; MALE; NEEDS ASSESSMENT; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 0036053930     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014492517088     Document Type: Review

References (77)

1. The treated natural history of high risk superficial bladder cancer: 15-year outcome
2. Natural history of superficial bladder cancer
3. Progression of T1 tumors: Better staging or better biology? Reply
4. Management of T1 G3 bladder carcinomas
5. Multivariate analysis of the prognostic factors of primary superficial bladder cancer
6. Late invasive recurrence despite long-term surveillance for superficial bladder cancer
7. The treated natural history of high risk superficial bladder cancer: Fifteen year outcome
8. Use of clinicopathological and immunohistochemical factors to predict multiple recurrences among patients with superficial TCC of the bladder
9. Tumour recurrence and progression following conservative management for T1G3 transitional cell carcinoma of the bladder
10. Can p53 help select patients with invasive bladder cancer for bladder preservation?
11. A critical analysis of the sue of p53 as a marker for management of bladder cancer
12. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression
13. p53 immunoreactivity in biopsy specimens of T1 G3 transitional cell carcinoma of the bladder - A helpful parameter in guiding the decision for or against cystectomy
14. Infiltrating carcinoma of the bladder: Relation of depth and penetration of the bladder wall to incidence of local extension and metastases
15. Is microstaging of early invasive cancer of the urinary bladder possible or useful?
16. Risk assessment of T1 transitional cell carcinoma of the bladder using p53 immunohistochemistry and pathologic substaging
17. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: A new proposal
18. Predicting cancer progression in patients with stage T1 bladder carcinoma
19. Uncertainty and outcome of invasive bladder tumors
20. The value of a second transurethral resection in evaluating patients with bladder tumors
21. Significance of second transurethral resection for T1 bladder cancer
22. Der wert der transurethralen nachresektion beim oberflächlichen Harnblasenkarzinom
23. Is a second transurethral resection (TUR) justified in patients with newly diagnosed superficial bladder cancer?
24. Fluorescence aided transurethral resection of superficial bladder cancer - Does it improve the quality of TUR?
25. pT1 bladder cancer
26. Therapy of superficial bladder carcinoma
27. Superficial bladder cancer treated with bacillus Calmette-Guerin: A multivariate analysis to factors affecting tumor progression
28. Ta and T1 bladder cancer: Location, recurrence and progression
29. Stage T1 grade 3 transitional cell carcinoma of the bladder: An unfavourable tumor?
30. T1 G3 bladder cancer. Management with transurethral resection only
31. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder
32. Zur Notwendigkeit der Nachresektion beim urothelialen Blasenkarzinom als Kontrolle der Erstresektion
33. Pathological aspects of pT1G3 urothelial carcinoma and carcinoma in situ
34. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial
35. The evaluation and follow-up of patients with Ta, Tcis and T1 bladder cancer
36. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction
37. Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder
38. Progression of T1 bladder tumors. Better staging or better biology. Editorial comment
39. The T1 bladder tumor
40. The natural history of a T1 bladder cancer: Life-long tumor diathesis
41. The natural history of a T1 bladder cancer: Life-long tumor diathesis
42. Stage T1 bladder cancer: Grade is the primary determinant for risk of muscle invasion
43. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome
44. A randomized trial of intravesical doxirubicin and immunotherapy with bacille Calmette-Guérin for transitional cell carcinoma of the bladder
45. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer. 10-year follow-up a perspective randomized trial
46. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis)
47. Editorial comment
48. Bladder wall penetration of intravesical mitomycin C in dogs
49. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients
50. Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall
51. Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in vitro: Evidence of a distinct BCG-activated killer (BAK) cell phenomen
52. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer
53. Intravesical Bacille Calmette-Guérin in stage T1 grade 3 bladder cancer therapy: A 7-year follow-up
54. Transurethral resection and sequential chemo-Immunoprophylaxis in primary T1G3 bladder cancer
55. Intravesical prophylaxis in bladder cancer: A meta-analysis
56. Random trial comparing intravesical chemo-induction with MMC to immunotherapy with BCG versus intravesical BCG, in patients with intermediate-high risk superficial bladder cancer. Preliminary results of the CUETO trial No. 93009
57. BCG does not seem to improve recurrence, progression or survival in T1G3 bladder cancer
58. Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy
59. The pT1 G3 bladder tumour
60. The management of invasive transitional cell carcinoma of the bladder. Results of definitive and preoperative therapy in 390 patients treated at the Prince of Wales Hospital, Sydney, Australia
61. Contemporary results of radical radiotherapy for bladder transitional cell carcinoma in a district general hospital with cancer-center status
62. Radiation therapy in regionally advanced bladder cancer
63. When intravesical measures fail - Indications for cystectomy in superficial disease
64. Radical cystectomy - Often to late?
65. The role of radical cystectomy in the management of high grade superficial bladder cancer (pTa, pT1, Cis and pT2)
66. Oberflächliches harnblasenkarzinom T1G3: Welche patienten sind kandidaten für eine zystektomie
67. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder
68. Local recurrence and survival following nerve sparing radical cystoprostatectomy
69. Office evaluation and management of bladder neoplasms
70. Extravesical tumor relapse in patients with superficial bladder tumors
71. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years
72. Intravesical instillation of epirubicin hydrochloride in superficial bladder tumor, prophylactic and therapeutic instillation for carcinoma in situ
73. A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin Rivm treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder
74. Cystectomy for superficial bladder cancer
75. Radical cystectomy for historical and pathologic T1, N0, M0 (stage A) transitional cell cancer. Need for adjuvant systemic chemotherapy?
76. Results of contemporary radical cystectomy for invasive bladder cancer: A clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification
77. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin Therapy